NO20015227L - Fremgangsmate for a oke effektiviteten til anti-cancer midler - Google Patents

Fremgangsmate for a oke effektiviteten til anti-cancer midler

Info

Publication number
NO20015227L
NO20015227L NO20015227A NO20015227A NO20015227L NO 20015227 L NO20015227 L NO 20015227L NO 20015227 A NO20015227 A NO 20015227A NO 20015227 A NO20015227 A NO 20015227A NO 20015227 L NO20015227 L NO 20015227L
Authority
NO
Norway
Prior art keywords
effectiveness
increasing
cancer agents
cancer
agents
Prior art date
Application number
NO20015227A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015227D0 (no
Inventor
Steven M Piver
David Silver
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of NO20015227D0 publication Critical patent/NO20015227D0/no
Publication of NO20015227L publication Critical patent/NO20015227L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
NO20015227A 1999-04-27 2001-10-25 Fremgangsmate for a oke effektiviteten til anti-cancer midler NO20015227L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
NO20015227D0 NO20015227D0 (no) 2001-10-25
NO20015227L true NO20015227L (no) 2001-12-27

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015227A NO20015227L (no) 1999-04-27 2001-10-25 Fremgangsmate for a oke effektiviteten til anti-cancer midler

Country Status (18)

Country Link
US (3) US6171620B1 (https=)
EP (1) EP1212068A4 (https=)
JP (1) JP2002542296A (https=)
KR (1) KR100693796B1 (https=)
CN (1) CN1188137C (https=)
AU (1) AU781301B2 (https=)
BG (1) BG64940B1 (https=)
BR (1) BR0010082A (https=)
CA (1) CA2368618C (https=)
HU (1) HUP0200840A3 (https=)
IL (1) IL146012A0 (https=)
MX (1) MXPA01010899A (https=)
NO (1) NO20015227L (https=)
NZ (1) NZ514521A (https=)
PL (1) PL350918A1 (https=)
RU (1) RU2271829C2 (https=)
WO (1) WO2000064455A1 (https=)
ZA (1) ZA200108012B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2232613T3 (es) 2000-04-26 2005-06-01 Cellegy Pharmaceuticals, Inc Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno.
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
US20110142834A1 (en) * 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
KR100693796B1 (ko) 2007-03-12
HUP0200840A3 (en) 2003-04-28
US6620779B2 (en) 2003-09-16
BG106057A (en) 2002-04-30
IL146012A0 (en) 2002-07-25
AU781301B2 (en) 2005-05-12
CA2368618A1 (en) 2000-11-02
EP1212068A1 (en) 2002-06-12
ZA200108012B (en) 2003-03-26
JP2002542296A (ja) 2002-12-10
AU4486300A (en) 2000-11-10
PL350918A1 (en) 2003-02-10
BG64940B1 (bg) 2006-10-31
CN1188137C (zh) 2005-02-09
US6171620B1 (en) 2001-01-09
MXPA01010899A (es) 2003-06-24
CN1352561A (zh) 2002-06-05
HUP0200840A2 (hu) 2002-07-29
US20020198153A1 (en) 2002-12-26
NZ514521A (en) 2003-07-25
BR0010082A (pt) 2002-01-15
WO2000064455A1 (en) 2000-11-02
RU2271829C2 (ru) 2006-03-20
NO20015227D0 (no) 2001-10-25
US20010000730A1 (en) 2001-05-03
EP1212068A4 (en) 2007-03-14
US6426094B2 (en) 2002-07-30
KR20020000557A (ko) 2002-01-05
CA2368618C (en) 2011-03-01

Similar Documents

Publication Publication Date Title
NO20015227L (no) Fremgangsmate for a oke effektiviteten til anti-cancer midler
NO20016169L (no) Hydraulisk setteverktöy
PT1181017E (pt) Inibidores de metaloproteases
NO20014944D0 (no) Prosessering for soniske bölgeformer
PT1280795E (pt) Derivados de carbamoiloalquil-azolio n-substituidos
DE60007050D1 (de) IMC-Verfahren
DE60016267D1 (de) Nietvorrichtung
DE60110919D1 (de) Modulare antiseismische vorrichtung zum schutz von gebäuden
ATE218675T1 (de) Befestigungsmittel
NO20014926L (no) Farmasöytiske forbindelser
ITMI20001543A0 (it) Spray scintillante per biancheria
DE60029393D1 (de) Bolzen
DE60027109D1 (de) Vorrichtung zum Eliminieren von Blasen
NO20013769L (no) Kalsilytiske forbindelser
DE60014790D1 (de) Vorrichtung zum Reduzieren von Rauschen
NO20020466D0 (no) Kalsilytiske forbindelser
ATE244992T1 (de) Sprühvorrichtung
DE50003014D1 (de) N-substituierte perhydrodiazine
DE60002824D1 (de) System zum Entwerfen von Primern
DE50003324D1 (de) Pulverkraftbetriebenes Setzgerät
FIU990058U0 (fi) Pylväs
DE60006028D1 (de) Aminobutyronitril Mischung
ATA36099A (de) Stoffgemisch
ITRM990062U1 (it) Progetto x
FI20000567A0 (fi) Kiinnityselin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application